1. Home
  2. CYCU vs PCSA Comparison

CYCU vs PCSA Comparison

Compare CYCU & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cycurion Inc.

CYCU

Cycurion Inc.

N/A

Current Price

$1.64

Market Cap

7.8M

Sector

N/A

ML Signal

N/A

Logo Processa Pharmaceuticals Inc.

PCSA

Processa Pharmaceuticals Inc.

N/A

Current Price

$2.80

Market Cap

8.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CYCU
PCSA
Founded
2017
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.8M
8.0M
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
CYCU
PCSA
Price
$1.64
$2.80
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$7.00
$25.00
AVG Volume (30 Days)
82.3K
34.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
54.36
EPS
N/A
N/A
Revenue
N/A
$5,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$5.54
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$0.11
52 Week High
$7.13
$8.88

Technical Indicators

Market Signals
Indicator
CYCU
PCSA
Relative Strength Index (RSI) 35.48 57.48
Support Level $1.62 $0.21
Resistance Level $2.91 $3.80
Average True Range (ATR) 0.12 0.28
MACD 0.02 0.10
Stochastic Oscillator 28.24 76.92

Price Performance

Historical Comparison
CYCU
PCSA

About CYCU Cycurion Inc.

Cycurion Inc. provides information technology security solutions through its subsidiaries. The Company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).

About PCSA Processa Pharmaceuticals Inc.

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

Share on Social Networks: